Personalized Treatment With Therapeutic Nicotine Helps Smokers Quit



    Experts gather at medical meeting in Dublin to discuss more personalized
treatment strategies
    

    
    DUBLIN, April 28 /PRNewswire/ -- Emerging research presented today at a
symposium during the Society for Research on Nicotine and Tobacco (SRNT) shows
that optimizing therapeutic nicotine products through new uses can
significantly enhance efficacy while offering more ways of quitting.  Global
leaders in smoking cessation discussed clinical study and real-world results
that highlight how these innovative treatment approaches go beyond the
established and common uses of therapeutic nicotine to offer smokers
encouraging new options in personalized quitting.(1)
    

    
    Studies discussed at the symposium analyzed the efficacy of using
therapeutic nicotine in different ways prior to quitting, while reducing
cigarette consumption, in combination with other therapeutic nicotine
products, and to prevent relapse after successfully quitting.(2)  Additional
research assessed the use of therapeutic nicotine treatment among smokers who
have not made a commitment to quit, showing that approaching quitting smoking
by gradual reduction may be an effective method for this group of smokers.(3) 
Further, a panel of experts representing different healthcare systems across
the globe highlighted innovative and effective uses of therapeutic nicotine
from a clinical, regulatory, patient and system perspective.  The global
leaders reviewed opportunities to improve clinical treatment, discussed
potential barriers and shared successes and best practices from their
countries.
    

    
    "A 'one size fits all' approach to helping smokers quit is becoming a
thing of the past.  Recent studies have found new ways for therapeutic
nicotine to reach a broader population of smokers," said John Hughes, MD,
professor of psychiatry at the University of Vermont and an expert consultant
to GlaxoSmithKline Consumer Healthcare.  "These new uses can help smokers who
have not responded to or been interested in traditional uses of therapeutic
nicotine medications."
    

    
    Additionally, a survey presented at the SRNT meeting identified different
groups of smokers based on readiness to quit.  The survey found that many
smoker groups had significant interest in the newest form of therapeutic
nicotine, NiQuitin Minis(R).(4)  Not only were smokers who were ready to quit
interested in NiQuitin Minis, but even smokers who were less ready to quit -
those who are disengaged from quitting, procrastinate about quitting, or are
ambivalent about quitting smoking - show a significant increase of interest in
NiQuitin Minis.  The small, fast-dissolving nicotine lozenge dissolves in a
fraction of the time required for the original lozenge.
    

    
    The survey identified 14 percent of all French smokers as Serious
Quitters who cite many reasons to quit, are ready to quit in the next three
months, and have previously used medications for quitting.  These smokers were
most receptive to current therapeutic nicotine products, and also showed the
strongest interest in NiQuitin Minis.  The survey also found large groups of
smokers that were not ready to quit, including: Ambivalent smokers (26
percent) want to quit, but cited just as many reasons against quitting as for
quitting.  Procrastinators (25 percent) expressed interest in quitting, but
would not commit to a specific time-frame.  Content Smokers (18 percent) have
tried to quit before, but were now disengaged from quitting.  The majority in
all three groups was not interested in current therapeutic nicotine
medications.  However, compared to current nicotine patch, gum, and lozenges,
all three groups showed significantly increased interest in this new form of
therapeutic nicotine, comprised of a small, fast-dissolving lozenge described
as offering rapid craving relief, NiQuitin Minis.(4)
    

    
    "Although most smokers say they are interested in quitting, only a
minority make a quit attempt in any given year, and of those who do attempt to
quit, most of those attempts are unassisted," said Saul Shiffman, PhD,
researcher and professor in the departments of psychology and pharmaceutical
science at the University of Pittsburgh and a consultant to GlaxoSmithKline
Consumer Healthcare.  "Therapeutic nicotine products have been shown to double
a smoker's chance of quitting versus cold turkey.(5)  As the newest
therapeutic nicotine product, the NiQuitin Minis lozenge is a welcome
addition."
    

    
    Therapeutic nicotine medications, including the NiQuitin lozenge and
patch (brand name Nicabate in Australia and Commit and NicoDerm in the United
States), can help relieve withdrawal symptoms during smoking cessation.(6) 
Research from more than 110 clinical trials involving over 40,000 participants
have established the safety and efficacy profile of therapeutic nicotine
products when used as directed.(5)  Therapeutic nicotine is recommended as a
first-line treatment for smoking addiction in United States, United Kingdom
and World Health Organization (WHO) guidelines.(6,7,8)  To date, GSK's
therapeutic nicotine has helped more than six million people around the world
quit smoking, and as a result, has greatly reduced their exposure to the risks
of cancer and other smoking-related diseases.(9)
    

    
    GlaxoSmithKline's line of therapeutic nicotine products are available in
thousands of retail outlets and pharmacies worldwide.  These products are
designed specifically to break the addiction cycle by offering a gradual,
controlled delivery of nicotine to the body, helping to relieve withdrawal
symptoms.
    

    About the Symposium
    
    The symposium entitled, "Pushing the Envelope: Optimizing the Efficacy of
Therapeutic Nicotine," was supported by an unrestricted educational grant from
GlaxoSmithKline Consumer Healthcare.  Featured presenters include:
    
    --  Using therapeutic nicotine to optimize efficacy - Dr. Saul Shiffman:
        University of Pittsburgh
    --  Applying therapeutic nicotine to new populations of smokers - Dr. John
        Hughes: University of Vermont

    --  Optimizing therapeutic nicotine use in clinical treatment (panel) -
Dr.
        Renee Bittoun: University of Sydney, Dr. Jonathan Foulds: UMDNJ School
        of Public Health, Jan Holding: UK National Health Service, Mitch
        Zeller: Pinney Associates, Bethesda, MD (moderator)


    About the NiQuitin Minis Lozenge Survey
    
    The survey, entitled, "Appealing to Smokers Who Are Not Ready to Quit,"
conducted by GSK Consumer Healthcare, was based off of a survey conducted in
France among 1,028 adult smokers, over 18 years old from a national research
panel; data were weighted to represent the French population.  Based on
current smoking behaviour and attitudes, nicotine dependence, and quitting
history and attitudes, respondents were clustered using latent class analysis
to identify subgroups of smokers.
    

    About GlaxoSmithKline Consumer Healthcare
    
    GlaxoSmithKline Consumer Healthcare is one of the world's largest
over-the-counter consumer healthcare products companies.  Its more than 30
well-known brands include the leading smoking cessation products, NicoDerm(R)
CQ and Commit(R), NiQuitin and Nicabate, as well as many medicine cabinet
staples such as Aquafresh(R) Panadol(R), Horlicks(R), Sensodyne(R) and
Lucozade(R).  GlaxoSmithKline Consumer Healthcare continues to develop
innovative products to help all smokers find their best support system and
achieve their goal of being cigarette free.
    

    About GlaxoSmithKline
    
    GlaxoSmithKline is one of the world's leading research-based
pharmaceutical and consumer healthcare companies.  GlaxoSmithKline is
committed to improving the quality of human life by enabling people to do
more, feel better and live longer.
    

    

    
    (1) Shiffman et al. Pushing the envelope: optimizing the efficacy of
    therapeutic nicotine. SRNT sponsored symposium Dublin. April 2009.
    (2) Shiffman, Saul. New ways of using therapeutic nicotine to increase
    efficacy. Presentation for SRNT sponsored symposium. Dublin. April 2009.
    (3) Hughes, John. Extending therapeutic nicotine use to new populations of
    smokers. Presentation for SRNT sponsored symposium. Dublin. April 2009.
    (4) Shiffman, Saul. Appealing to smokers varying in readiness to quit.
    Poster. SRNT annual meeting. Dublin. April 2009.
    (5) Silagy et al. Nicotine replacement therapy for smoking cessation
    (Cochrane Review). In: The Cochrane Library, Issue 1, 2004.  Chichester,
    UK: John Wiley & Sons, LTD
    (6) Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and
    Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S.
    Department of Health and Human Services. Public Health Service. May 2008.
    (7) World Health Organization. WHO Report on the Global Tobacco Epidemic,
    2008.  Geneva: World | Health Organization; 2008 [cited 2008 Mar 21].
    Available from: http://www.who.int/tobacco/mpower/en/
    (8) NICE. 2002. Guidance on the use of nicotine replacement therapy (NRT)
    and bupropion for smoking cessation.  Technology Appraisal Guidance -
    No.39.
    (9) GSK data on file.

    

    
    Media      Teresa Calanni, GolinHarris
    Contacts:  312 729 4229, tcalanni@golinharris.com
    

    
               Brian Jones,
               GlaxoSmithKline Consumer Healthcare
               00+1+215+751+3415, Brian.L.Jones@gsk.com



    




For further information:

For further information: Teresa Calanni of GolinHarris, +1-312-729-4229,
tcalanni@golinharris.com, for GlaxoSmithKline Consumer Healthcare; or Brian
Jones of GlaxoSmithKline Consumer Healthcare, +1-215-751-3415,
Brian.L.Jones@gsk.com

Organization Profile

GLAXOSMITHKLINE CONSUMER HEALTHCARE

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890